Advanced age

Female gender

Concomitant administration of cardiotoxic agents

Ÿ Etoposide (Etopophos®, Vepesid®)**

Ÿ Daunorubicin (Cerubidine®)**

Pre-existing cardiovascular disease

Ÿ Significant coronary artery disease

Ÿ Diffuse or multiple corronary artery lesions

Ÿ Recent radial artery coronary artery bypass grafting

Ÿ Those already requiring a calcium channel blocker or nitrates to control vasospasm or angina

Radiation

Ÿ Mediastinal

Ÿ Chest

Ÿ Neck

Cumulative dosing regimens:

Ÿ Daunorubicin (Cerubidine®)**

Ÿ Epirubicin (Pharmorubicin®)**

Ÿ Mitomycin-C (Mutamycin®)**

Maximal or total dose administered during a day/course:

Ÿ Cyclophosphamide (Cytoxan®, Neosar®)**

Ÿ Ifosfamide (Mitoxana®)**

Ÿ Carmustine (BiCNU®)**

Ÿ 5-Fluorouracil (Adrucil®)**

Ÿ Cytarabine (Cytosar®)**

Rate of administration:

Ÿ Daunorubicin (Cerubidine®)**

Ÿ Ifosfamide (Mitoxana®)**

Ÿ 5-Fluorouracil (Adrucil®)**

Prior chemotherapy and/or cardiotoxicity:

Ÿ Daunorubicin (Cerubidine®)**

Electrolyte imbalances

Ÿ hypokalaemia

Ÿ hypomagnesaemia

Ÿ hypophosphatemia